# Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.

> **NCT02709486** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 849 (actual)

## Conditions studied

- Osteoarthritis, Hip
- Osteoarthritis, Knee

## Interventions

- **DRUG:** Tanezumab
- **DRUG:** Tanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02709486
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-02
- **Primary completion:** 2018-06-08
- **Final completion:** 2018-11-14
- **Target enrollment:** 849 (ACTUAL)
- **Last updated:** 2019-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02709486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02709486, "Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02709486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*